Toru Hosoda, MD, PhD

Sakakibara Heart Institute, Fuchu, Tokyo, Japan

After graduating and obtaining M.D. and Ph.D. degrees from the University of Tokyo, Dr. Hosoda carried out basic researches and clinical practices on cardiovascular medicine. Subsequently, over the last decade at the New York Medical College as well as at the Brigham and Women’s Hospital, Harvard Medical School, he has been committed to explore the field of regenerative medicine, especially the concept of myocardial renewal and repair by resident stem cells. After performing numerous investigations indicating the safety and efficacy of the stem cell administration in the preclinical settings of cardiac disease models, the group had moved on to the clinical arena; in the monumental SCIPIO trial, 20 severe ischemic heart failure patients received the injection of their own c-kit-positive cardiac stem cells following expansion in vitro, which demonstrated the feasibility and safety of this treatment. Following his running of a translational laboratory at the Tokai University in Japan for 6 years, Dr. Hosoda is currently working at the Sakakibara Heart Institute to initiate a clinical trial utilizing autologous cardiac stem cells for chronic heart failure patients.

Terms of Appointment: May 2015- Apr 2017; May 2017- Apr 2019; May 2019- Apr 2021